Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...
Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of breast cancer-specific survival. ...HER3 expression was... significantly associated with ...
A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the drug later this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback